PARADIGM REPORTS RECORD SALES IN DECEMBER

Contacts:

Stanley Wunderlich
Consulting For Strategic Growth,Ltd.
Corporate Development Consultants
Public Relations   
Tel: 800-625-2236         
Fax: 516-625-4523         
Email: cfsg@iname.com   

John W. Hemmer
Director of Shareholder Relations
Paradigm Medical Industries, Inc.
Tel: 914-762-2946
Fax: 914-762-4322
Web site: www.paradigm-medical.com

   SALT LAKE CITY, UT – January 24, 2001 - Paradigm Medical Industries, Inc. (NASDAQ:PMED) announced today that the company achieved record sales for a single month in December of $1.26 million.

Were very proud of this achievement and look forward to more of this kind of performance now that our flagship product, the Photon Laser System for Cataract removal, is approved for sale in Europe" commented Thomas Motter, Paradigms Chairman and Chief Executive Officer.

The Photon approval in Europe is just one of a number of factors impacting the companys ability to generate record revenues. Our recently FDA approved Ultrasound Workstation for Eye Care combining several systems is proving to be an outstanding success. The company had record orders at the annual American Academy of Ophthalmology Trade Show last October in Dallas. As more of our products are sold an ongoing revenue stream is generated, in some cases exponentially, from the disposable and consumable products they use", Mr. Motter stated.

Paradigm Medical Industries, Inc., currently develops, manufactures and markets surgical and diagnostic high-tech breakthrough" proprietary equipment and consumable products in medicine. The companys corporate offices are located at 2355 South 1070 West, Salt Lake City, Utah 84119. Call 801-977-8970 or visit us at our web site at www.paradigm-medical.com.

# # #

This press release contains forward-looking statement that, if not verifiable historical fact, may be viewed as forward-looking statements that could predict future events or outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risks and uncertainties and accordingly, Paradigm actual results may differ significantly from the results discussed or implied in such forward-looking statements.